Onyx Biotec Ltd
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
- Market Cap ₹ 65.3 Cr.
- Current Price ₹ 36.0
- High / Low ₹ 49.6 / 24.2
- Stock P/E
- Book Value ₹ 30.6
- Dividend Yield 0.00 %
- ROCE 1.15 %
- ROE -0.38 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.18 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -23.4%
- Company has a low return on equity of 6.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 44.86 | 39.49 | 53.75 | 61.95 | 69.47 | |
| Sales growth | -11.97% | +36.11% | +15.26% | +12.14% | |
| 39.09 | 34.99 | 45.36 | 51.57 | 66.06 | |
| Operating Profit | 5.77 | 4.50 | 8.39 | 10.38 | 3.41 |
| OPM % | 12.86% | 11.40% | 15.61% | 16.76% | 4.91% |
| 0.12 | 0.11 | 0.13 | 1.17 | 0.44 | |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.22 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 |
| Profit before tax | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 |
| Tax % | 11.61% | 27.45% | 19.15% | 23.46% | -50.00% |
| 3.35 | 1.84 | 3.63 | 4.95 | -0.21 | |
| EPS in Rs | 2.84 | 1.56 | 2.72 | 2.73 | -0.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -106% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.30 | 11.97 | 37.49 | 37.28 |
| 12.25 | 29.23 | 30.78 | 12.46 | 15.17 | |
| 8.22 | 11.30 | 18.07 | 23.17 | 24.58 | |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.16 |
| 17.23 | 42.50 | 43.48 | 40.90 | 39.16 | |
| CWIP | 4.02 | 0.00 | 0.00 | 0.00 | 3.68 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15.59 | 16.23 | 30.66 | 50.35 | 52.32 | |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.16 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.49 | 1.96 | 1.52 | 1.42 | -1.49 | |
| -5.78 | -22.68 | -3.15 | 0.66 | -4.58 | |
| 5.20 | 16.43 | 3.09 | 5.07 | 1.50 | |
| Net Cash Flow | -0.09 | -4.30 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.30 | -20.78 | -1.70 | 1.91 | -6.48 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 8% | 44% | 18% | 14% | -44% |
Ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104.37 | 119.19 | 144.49 |
| Inventory Days | 41.98 | 109.92 | 92.94 | 150.14 | 99.20 |
| Days Payable | 59.46 | 120.16 | 140.83 | 156.02 | 124.70 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113.32 | 118.98 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | 8.23% | 12.85% | 12.16% | 1.15% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Employee Benefits Expense INR Lakhs |
|
||
| Permanent Employees count |
|||
| Production Machines (Unit-1 SWFI) count |
|||
Extracted by Screener AI
Documents
Announcements
-
Public Announcement-Open Offer
- VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of offer opening public announcement cum corrigendum to the detailed public statement to …
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Corporate governance provisions not applicable for quarter ended September 30, 2026; company listed on NSE Emerge.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.
-
Updates
- Independent Directors' open offer recommendation published on 8 Oct 2026 for acquisition of 26% of Onyx Biotec.
-
Committee Meeting Updates
- Independent directors reviewed open offer for 47,14,372 shares, 26% stake, by four acquirers.
Business Overview:[1]
OBL is a pharmaceutical company engaged in the manufacture, sale, and distribution of generic and proprietary pharmaceutical products. The company develops, manufactures and distributes generic and branded pharmaceutical products in various forms like (WFI) Water for Injection, Dry Powder Injections, Dry Powder Syrup.